After the clinical application of tyrosine kinase inhibitor (TKI) blocking BCR/ABL kinase activity, the prognosis of children with CML and Ph+ ALL has improved dramatically. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.